Krystal Biotech, Inc. — Form 8-K
Filed October 15, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Krystal Biotech announced positive Phase 1/2 pilot data for KB113, an intratumoral immunotherapy, in three patients with Gorlin syndrome. Over 80% of 83 assessed basal cell carcinoma lesions regressed (50.6% showed ≥50% reduction); notably, 85.1% of non-injected lesions also regressed, suggesting an abscopal effect. All three biopsied lesions with ≥90% regression showed histologically confirmed complete response; adverse events were mild-to-moderate and transient. The company initiated FDA discussions for advanced development.
Why this rating
Early-stage proof-of-concept in three patients for new indication (Gorlin syndrome BCC) is encouraging but small cohort with no efficacy control; modest development milestone for a $3.5B company with approved commercial product.
See more from October 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.